Pfizer Research Grant Request for Proposals: The Role of RSV in Functional Decline and Healthcare Dependency in Hospitalized Adults
Pfizer funds research in Italy on how RSV infection in hospitalized adults leads to functional decline and healthcare dependency, aiming to improve prevention and post-discharge care strategies.
Funder: Pfizer Inc.
Due Dates: October 19, 2026 (Submission Deadline)
Funding Amounts: Up to EUR 150,000 per project (18 months max); total program budget EUR 300,000
Summary: Funds research on RSV-related functional decline and healthcare dependency in hospitalized adults in Italy to inform prevention and post-discharge care strategies.
Key Information: Applicants must be Italy-based institutions; individuals are not eligible.
Description
This competitive grant program from Pfizer supports independent research projects that generate real-world evidence on the functional and non-respiratory burden of Respiratory Syncytial Virus (RSV) infection in hospitalized adults in Italy. The aim is to characterize functional decline, loss of independence, and increased healthcare dependency following RSV-related hospitalization, especially in older adults and those with pre-existing vulnerabilities. Projects should utilize routinely collected hospital data and are encouraged to examine epidemiological characteristics, acute non-respiratory complications, and post-discharge outcomes. The ultimate goal is to inform risk stratification, targeted prevention, and development of post-discharge care pathways for high-risk adult populations.
